Molecules that bind to cd94/nkg2a heterodimer polypeptides
US-2024415889-A1 · Dec 19, 2024 · US
Bispecific EGFR/c-Met antibodies
US9593164B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9593164-B2 |
| Application number | US-201314086588-A |
| Country | US |
| Kind code | B2 |
| Filing date | Nov 21, 2013 |
| Priority date | Nov 21, 2012 |
| Publication date | Mar 14, 2017 |
| Grant date | Mar 14, 2017 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
Bispecific EGFR/c-Met antibodies and methods of making and using the molecules.
First claim
Opening claim text (preview).
What is claimed: 1. An isolated bispecific epidermal growth factor receptor (EGFR)/hepatocyte growth factor receptor (c-Met) antibody, comprising: a) a first heavy chain (HC1); b) a second heavy chain (HC2); c) a first light chain (LC1); and d) a second light chain (LC2) wherein the HC1, the LC1, the HC2 and the LC2 comprise amino acid sequences of SEQ ID NOs: 199, 200, 201 and 202, respectively. 2. A pharmaceutical composition comprising the bispecific antibody of claim 1 and a pharmaceutically acceptable carrier.
Assignees
Inventors
Classifications
specific for metastasis · CPC title
Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title
Antineoplastic agents · CPC title
Antagonist effect on antigen, e.g. neutralization or inhibition of binding · CPC title
Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9593164B2 cover?
- Bispecific EGFR/c-Met antibodies and methods of making and using the molecules.
- Who is the assignee on this patent?
- Janssen Biotech Inc
- What technology area does this patent fall under?
- Primary CPC classification C07K16/2863. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Mar 14 2017 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).